Lia K. Strait

Lia K. Strait

Auto-generated profile, based on publicly available information

Lia K. Strait


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
ESElisabeth Schwiebert
Elisabeth Schwiebert
LSLia K. Strait
Lia K. Strait
SMSamuel G. Moore
Samuel G. Moore
DGDavid A Gaul
David A Gaul
FFFacundo M. Fernández
Facundo M. Fernández
RGRobert E Guldberg
Robert E Guldberg
Understanding the biological mechanisms behind fracture nonunions and their treatments remains incomplete. Since these mechanisms are linked to phenotypic expression, studying the longitudinal metabolic profile of bone regeneration has emerged as a potential way to better understand healing progress and treatment effectiveness. In this study, we tracked the serum metabolome of rats with critically-sized femoral defects treated with either a control, a minimum effective dose, or a supraphysiologic dose of rhBMP-2 over time. We observed distinct changes in the metabolome across control, impaired healing, and rhBMP-2-treated animals. Early in the process, we saw increased levels of metabolites that support angiogenesis in the rhBMP-2 groups. Supraphysiologic doses of rhBMP-2 significantly affected metabolite expression, especially in pathways related to angiogenesis, fatty acid metabolism, and ATP production. These longitudinal trends and individual metabolite changes provide a deeper understanding of rhBMP-2’s mechanisms, improve our knowledge of its biological effects—guiding appropriate dosing—and offer a metabolic profile that may indicate healing impairment.

15 May 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
LSLia K. Strait
Lia K. Strait
LRLucy Rose
Lucy Rose
TGTyler Guyer
Tyler Guyer
KJKimberly A. Jones
Kimberly A. Jones
GDGraham J. DeKeyser
Graham J. DeKeyser
RGRobert E Guldberg
Robert E Guldberg
Bone morphogenetic proteins (BMPs) are among the most potent clinical therapeutics for promoting bone regeneration, yet their use is limited by potential adverse events such as heterotopic bone formation, osteolysis, and soft tissue inflammation. Sustained release delivery systems may reduce the minimum effective BMP dose needed to induce functional bone healing but have yet to be fully characterized or translated to clinical use. Here, we utilized a rat model of segmental femur defect healing to investigate the dose-dependent inflammatory effects of BMP delivery in a hydrogel-based system by profiling local and systemic immune responses. Defects were treated with the delivery vehicle only (control), a minimum effective dose of BMP-2, or a supraphysiologic dose of BMP-2. The minimum effective BMP-2 dose induced comparable bone formation within the defects but significantly less heterotopic ossification outside the defects relative to the supraphysiologic dose. Immune profiling revealed significant dose-dependent effects of BMP-2 delivery on cellular and proteomic signatures both locally and systemically. Notably, however, no significant differences in immune response markers were detected between the vehicle only control and minimum effective dose groups at any timepoint. This study confirms that BMP-2 delivered at high doses incites strong inflammatory responses locally and systemically, but sustained delivery of a minimum effective dose can regenerate bone without provoking heterotopic bone formation or inflammatory side effects.